Separation methods of T cells, natural killer, and dendritic cells from peripheral blood of cancer patients using interleukin-2 and functional analysis of natural killer cells after separation

Immunopharmacology and Immunotoxicology

Volumn 29, Issue 1, 2007, Pages 31-47

  Matsushita, Norimasa ^a,b,d   Aruga, Atsushi ^a,b   Kobayashi, Yasunobu ^c   Tanigawa, Keishi ^c   Yamamoto, Masakazu ^b  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c JB Therapeutics   (Japan)

^d NONE   (Japan)

Author keywords

Adherent NK Cell; CD3 Activated T Cell; Immunotherapy; Interleukin 2; Natural Cytotoxicity Receptor

Indexed keywords

INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; NKP30 PROTEIN; NKP44 PROTEIN; NKP46 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PATIENT; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL SEPARATION; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; METHODOLOGY; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL SEPARATION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 34247573937     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970701277791     Document Type: Article

References (34)

1. Rosenberg, S.A.; Yang, J.C.; Robbins, P.F.; Wunderlich, J.R.; Hwu, P.; Sherry, R.M.; Schwartzentruber, D.J.; Topalian, S.L.; Restifo, N.P.; Filie, A.; Chang, R.; Dudley, M.E. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003, 26 (5), 385-393.
2. Restifo, N.P.; Marincola, F.M.; Kawakami, Y.; Taubenberger, J.; Yannelli, J.R.; Rosenberg, S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996, 88 (2), 100-108.
3. Fujiwara, K.; Higashi, T.; Nouso, K.; Nakatsukasa, H.; Kobayashi, Y.; Uemura, M.; Nakamura, S.; Sato, S.; Hanafusa, T.; Yumoto, Y.; Naito, I.; Shiratori, Y. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J. Gastroent. Hepatol. 2004, 19 (10), 1121-1127.
4. Basse, P.; Herberman, R.B.; Nannmark, U.; Johansson, B.R.; Hokland, M.; Wasserman, K.; Goldfarb, R.H. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 1991, 174 (2), 479-488.
5. Karre, K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 1995, 267 (5200), 978-979.
6. Whiteside, T.L.; Sung, M.W.; Nagashima, S.; Chikamatsu, K.; Okada, K.; Vujanovic, N.L. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Clin Cancer Res. 1998, 4 (5), 1135-1145.
7. Sacchi, M.; Vitolo, D.; Sedlmayr, P.; Rabinowich, H.; Johnson, J.T.; Herberman, R.B.; Whiteside, T.L. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int. J. Cancer 1991, 47 (5), 784-791.
8. Moretta, A.; Bottino, C.; Mingari, M.C.; Biassoni, R.; Moretta, L. What is a natural killer cell? Nat. Immunol. 2002, 3 (1), 6-8.
9. Melder, R.J.; Rosenfeld, C.S.; Herberman, R.B.; Whiteside, T.L. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man. Cancer Immunol Immunother. 1989, 29 (1), 67-73.
10. Melder, R.J.; Whiteside, T.L.; Vujanovic, N.L.; Hiserodt, J.C.; Herberman, R.B. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. 1988, 48 (12), 3461-3469.
11. Melder, R.J.; Walker, E.R.; Herberman, R.B.; Whiteside, T.L. Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells. J. Leukoc Biol. 1990, 48 (2), 163-173.
12. Biassoni, R.; Cantoni, C.; Marras, D.; Giron-Michel, J.; Falco, M.; Moretta, L., Dimasi, N. Human natural killer cell receptors: insights into their molecular function and structure. J. Cell Mol. Med. 2003, 7(4), 376-387.
13. Pessino, A.; Sivori, S.; Bottino, C.; Malaspina, A.; Morelli, L.; Moretta, L.; Biassoni R.; Moretta, A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 1998, 188 (5), 953-960.
14. Vitale, M.; Bottino, C.; Sivori, S.; Sanseverino, L.; Castriconi, R.; Marcenaro, E.; Augugliaro, R.; Moretta, L.; Moretta, A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 1998, 187 (12), 2065-2072.
15. Groh, V.; Wu, J.; Yee, C.; Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419 (6908), 734-738.
16. Grimm, E.A.; Robb, R.J.; Roth, J.A.; Neckers, L.M.; Lachman, L.B.; Wilson D.J.; Rosenberg, S.A. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J. Exp. Med. 1983, 158 (4), 1356-1361.
17. Aruga, A.; Yamauchi, K.; Takasaki, K.; Furukawa, T., Hanyu, F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer. 1991, 49 (1), 19-24.
18. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 1991, 9, 271-296.
19. Hart, D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997, 90 (9), 3245-3287.
20. Mayordomo, J.I.; Zorina, T.; Storkus, W.J.; Zitvogel, L.; Celluzzi, C.; Falo, L.D.; Melief, C.J.; Ildstad, S.T.; Kast, W.M.; Deleo, A.B.; et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995, 1 (12), 1297-302.
21. Fields, R.C.; Shimizu, K.; Mule, J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1998, 95 (16), 9482-9487.
22. Chang, A.E.; Redman, B.G.; Whitfield, J.R.; Nickoloff, B.J.; Braun, T.M.; Lee, P.P.; Geiger, J.D.; Mule, J.J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002, 8 (4), 1021-1032.
23. Geiger, J.D.; Hutchinson, R.J.; Hohenkirk, L.F.; McKenna, E.A.; Yanik, G.A.; Levine, J.E.; Chang, A.E.; Braun, T.M.; Mule, J.J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61 (23), 8513-8519.
24. Farag, S.S.; Fehniger, T.A.; Ruggeri, L.; Velardi, A.; Caligiuri, M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002, 100 (6), 1935-1947.
25. Frohn, C.; Schlenke, P.; Kirchner, H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology 1997, 92 (4), 567-570.
26. Takayama, T.; Sekine, T.; Makuuchi, M.; Yamasaki, S.; Kosuge, T.; Yamamoto, J.; Shimada, K.; Sakamoto, M.; Hirohashi, S.; Ohashi, Y.; Kakizoe, T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356 (9232), 802-807.
27. Liljefors, M.; Nilsson, B.; Hjelm Skog, A.L.; Ragnhammar, P.; Mellstedt, H.; Frodin, J.E. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int. J. Cancer 2003, 105 (5), 717-723.
28. Moretta, A.; Biassoni, R.; Bottino, C.; Mingari, M.C.; Moretta, L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000, 21 (5), 228-234.
29. Nagler, A.; Lanier L.L.; Cwirla S.; Phillips, J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. J. Immunol. 1989, 143 (10), 3183-3191.
30. Cooper, M.A.; Fehniger, T.A.; Turner, S.C.; Chen, K.S.; Ghaheri, B.A.; Ghayur, T.; Carson, W.E.; Caligiuri, M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97 (10), 3146-3151.
31. Piccioli, D.; Sbrana, S.; Melandri, E., Valiante, N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 2002, 195 (3), 335-341.
32. Kalinski, P.; Giermasz, A.; Nakamura, Y.; Basse, P.; Storkus, W.J.; Kirkwood, J.M., Mailliard, R.B. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol. Immunol. 2005, 42 (4), 535-539.
33. Ferlazzo, G.; Tsang, M.L.; Moretta, L.; Melioli, G.; Steinman, R.M.; Munz, C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 2002, 195 (3), 343-351.
34. Gerosa, F.; Baldani-Guerra, B.; Nisii, C.; Marchesini, V.; Carra, G.; Trinchieri, G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195 (3), 327-333.